Live Breaking News & Updates on Elbourne Hq With Additional Team Members Based Across The East Coast Of Australia

With over 110% revenue growth in the last two years, Accelagen announces move to new office space in Hawthorn East, Melbourne MELBOURNE, Australia, Sept. 20, 2022 /PRNewswire/ Accelagen, one of Australia's leading Contract Research Organisations, has taken new 472sqMoffice space in Hawthorn East following two years of rapid growth for the business. Now a multi-million dollarbusiness built up from a small consultancy in 2010, Accelagen's team of experts across its key service offerings; Clinical Trial Management, Regulatory Affairs, Strategic Consultation and the newly launched Biometrics team, work flexibly out of the Hawthorn East, Melbourne HQ with additional team members based across the East Coast of Australia, and partners in growing markets overseas. Accelagen's client acquisition has increased by 40%, including supporting clients to progress the development of two COVID-19 vaccine studies from a renowned international manufacturer during the height of the pandemic, ....

Greg Plunkett , Contract Research Organisations , Regulatory Affairs , Contract Research Organisation , Hawthorn East , Clinical Trial Management , Strategic Consultation , East Coast , Founder Greg Plunkett , Managing Director , With Over 110 Revenue Growth In The Last Two Years , Ccelagen Announces Move To New Office Space In Hawthorn East , Elbourne Melbourne , Sept 20 , 022 Prnewswire Accelagen , Ne Of Australia 39s Leading Contract Research Organisations , As Taken New 472sqmoffice Space In Hawthorn East Following Two Years Of Rapid Growth For The Business Nowa Multi Million Dollarbusiness Built Up Froma Small Consultancy 2010 , Ccelagen 39s Team Of Experts Across Its Key Service Offerings Clinical Trial Management , Regulatory Affairs , Trategic Consultation And The Newly Launched Biometrics Team , Ork Flexibly Out Of The Hawthorn East , Elbourne Hq With Additional Team Members Based Across The East Coast Of Australia , Nd Partners In Growing Markets Overseas Accelagen 39s Client Acquisition Has Increased By 40 , Ncluding Supporting Clients To Progress The Development Of Two Covid 19 Vaccine Studies Froma Renowned International Manufacturer During Height Pandemic , S Well As Key Breakthroughs In Targeted Cancer Treatments And New Technologies Intended For Antiviral Treatment Accelagen Is At The Forefront Of Full Service Bio Pharmaceutical Medical Device Development Worldwide Led By Ceo Founder Greg Plunkett , Hen Asked About The Motivation For Expansion ,